Association of Higher Defensin β-4 Genomic Copy Numbers with Behçet’s Disease in Iraqi Patients by Hameed, Ammar F. et al.
Departments of 1Dermatology and 3Pathology, College of Medicine, University of Baghdad, Baghdad, Iraq; 2Department of Dermatology, Jena University 
Hospital, Jena, Germany; 4Department of Dermatology, Baghdad Teaching Hospital, Baghdad, Iraq
*Corresponding Author e-mail: amarfaisal1976@yahoo.com
الرتابط بني أعداد النسخ اجلينومية املرتفعة لربوتني ديفنسني بيتا DEFB4( 4( وبني 
داء هبجت عند املرضى العراقيني
عمار حميد، �سامح جردات، ب�سام املو�سوي، خليفة ال�رسقي، مازن اإبراهيم، رافع احلياين، جونز نورقوار
abstract: Objectives: Behçet’s disease (BD) is an immune-mediated small vessel systemic vasculitis. Human 
β-defensins are antimicrobial peptides associated with many inflammatory diseases and are encoded by the 
β-defensin family of multiple-copy genes. However, their role in BD necessitates further investigation. The aim of 
the present study was to investigate the possible association of BD in its various clinical forms with defensin β-4 
(DEFB4) genomic copy numbers. Methods: This case-control study was conducted from January to September 
2011 and included 50 control subjects and 27 unrelated Iraqi BD patients registered at Baghdad Teaching Hospital, 
Bagdad, Iraq. Copy numbers of the DEFB4 gene were determined using the comparative cycle threshold method 
by duplex real-time polymerase chain reaction technology at the Department of Dermatology of Jena University 
Hospital, Jena, Germany. Results: DEFB4 genomic copy numbers were significantly higher in the BD group 
compared to the control group (P = 0.010). However, no statistically significant association was found between copy 
numbers and clinical variables within the BD group. Conclusion: The DEFB4 copy number polymorphism may be 
associated with BD; however, it is not associated with different clinical manifestations of the disease.
Keywords: Behçet Disease; beta-Defensins; Genetic Polymorphisms; Gene Copy Numbers; Iraq.
امللخ�ص: الهدف: داء بهجت هو التهاب مناعي جهازي ي�سيب الأوعية الدموية ال�سغرية. وبيتا ديفن�سني هي بيبتيدات م�سادة للميكروبات 
ترتبط بكثري من الأمرا�ض اللتهابية، وتكون م�سفرة يف عائلة بيتا ديفين�سني املكونة من مورثات )جينات( متعددة الن�سخ. غري اأن الدور 
الذي قد تلعبه تلك املورثات يف داء بهجت ما زال يحتاج ملزيد من الدرا�سة. ويهدف هذا البحث لدرا�سة الرتابط املمكن بني داء بهجت ب�سوره 
الإكلينيكية املختلفة وبني اأعداد الن�سخة اجلينومية DEFB4. الطريقة: اأجريت هذه الدرا�سة ال�ستعادية من يناير اإىل �سبتمرب 2011م و�سملت 
50 فردا �سحيحا )جمموعة �سابطة( و27 مري�سا عراقيا )لي�سوا باأقرباء( م�سابني بداء بهجت من امل�سجلني مب�ست�سفى بغداد التعليمي يف 
العراق. وحددت اأرقام مورثات DEFB4 بتقنية تفاعل الت�سل�سل البلومريزي بق�سم الأمرا�ض اجللدية يف م�ست�سفى اجلامعة بجينا يف اأملانيا. 
النتائج: وجد اأن اأرقام الن�سخة اجلينومية DEFB4 كانت اأعلى معنويا عند مر�سى داء بهجت عند املقارنة مع املجموعة ال�سابطة )0.010 
= P(. غري اأنه مل تكن هنالك اأي فروقات معنوية بني ن�سخ اأرقام مورثات DEFB4 والأعرا�ض الإكلينيكية للم�سابني باملر�ض. اخلال�صة: 
هنالك ارتباط بني تعدد اأ�سكال اأرقام DEFB4 وبني داء بهجت، رغم عدم وجود اأي ارتباط لها مع الأعرا�ض الإكلينيكية.
مفتاح الكلمات: داء بهجت؛ بيتا ديفن�سني؛ تعدد الأ�سكال الوراثية؛ اأعداد ن�سخ املورثات؛ العراق.
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Advances in Knowledge
- As part of its genetic pathogenesis, Behçet’s disease (BD) may be associated with the presence of a high number of human defensin β-4 
(DEFB4) genomic copy numbers, as observed among this sample of unrelated Iraqi BD patients.
- The DEFB4 genomic copy numbers in the healthy Iraqi control group were comparable to those observed in other populations.
Application to Patient Care
- BD has neither a specific diagnostic test nor a targeted course of therapy. As such, exploring the genetic basis of this autoimmune 
disease could improve understanding of its pathological mechanisms and promote the development of a more accurate diagnostic and 
therapeutic approach.
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Behçet’s disease (bd) is a chronic auto-immune disease characterised by multiple inflammatory lesions of the orogenital 
mucosa, eyes and skin with additional involvement 
of other organs in the body.1 BD is prevalent in 
the Mediterranean region and eastern Asia;2 Iraq 
is also known to have a relatively high prevalence 
of the disease.3 Although the precise pathogenesis 
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of BD remains unknown, genetic, immunological 
and environmental factors have been suggested to 
contribute to its development.2 A genetic basis for BD 
is supported by its high prevalence in certain 
geographic areas, the familial aggregation of cases 
and a strong association with human leukocyte 
antigen-B51.4,5 Moreover, single nucleotide polymor-
phism studies have revealed associations with several 
genes, including interferon regulatory factor 1 and 
tumour necrosis factor-α (TNF-α).6,7 
Human β-defensins (hBDs) are antimicrobial 
peptides expressed by various epithelial tissues. They 
are encoded by the multiple-copy β-defensin gene 
family, copies of which are clustered on the short arm 
of chromosome eight, including the human defensin 
β-2 gene synthesised by defensin β-4 (DEFB4).8 This 
β-defensin cluster has a genomic copy number of 
between two and 12 copies per genome, with a mode of 
four copies.9 Such variation in genomic copy numbers 
may play a role in innate immunity; research has shown 
that hBD-2 has the ability to function as a chemokine 
that attracts inflammatory cells, such as dendritic 
cells and T lymphocytes, to the inflamed tissues.10,11 
Thus, it is possible that variations in the DEFB4 
gene might influence an individual’s susceptibility to 
immune-mediated diseases. The antimicrobial and 
proinflammatory nature of these β-defensins has 
led many researchers to hypothesise that variations 
in gene dosage may affect the pathogenesis of many 
immunological diseases.12 Hence, the present study 
aimed to investigate genomic copy numbers of DEFB4 
in Iraqi BD patients in comparison with normal 
healthy controls. Various clinical manifestations of BD 
were also studied in association with DEFB4 genomic 
copy numbers.
Methods
This case-control study was conducted between 
January and September 2011 and included all unrelated 
Iraqi patients registered at the BD Clinic in Baghdad 
Teaching Hospital, Baghdad, Iraq (n = 27), and 
randomly selected healthy control subjects (n = 50). 
All of the BD patients fulfilled the International Study 
Group criteria for a diagnosis of BD, which requires 
the presence of recurrent oral ulcers plus at least two of 
the following symptoms: recurrent genital ulcerations, 
typical defined eye or skin lesions or a positive skin 
pathergy test (a skin hypersensitivity reaction to a 
non-specific physical insult).13,14 Any patient who did 
not fulfil these criteria was excluded from the study. 
The control group included healthy individuals who 
donated their blood to the central blood bank after 
confirmation that they were free from any symptoms 
or signs suggestive of BD.
Blood was collected from all of the subjects and 
genomic DNA was extracted from peripheral blood 
mononuclear cells by a standard phenol-chloroform 
method at the Department of Pathology in Baghdad 
Medical College, Baghdad. Samples were then stored 
at -20 °C and delivered to the Department of Dermato-
logy at Jena University Hospital, Jena, Germany. DNA 
concentrations and quality were then determined with 
a NanoDrop 1000 spectrophotometer (Nanodrop 
Technologies Inc., Thermo Fisher Scientific Inc., 
Wilmington, Delaware, USA) using the following 
settings: optical density (OD) at 260/280 ~1.8 and OD 
at 260/230 = 2.0–2.2. Samples were anonymised and 
the genomic copy number analysis was performed 
by individuals who were blinded to the relevant 
clinical information. 
Diploid DEFB4 genomic copy numbers (GenBank: 
AF040153.1)15 were determined by a duplex real-
time polymerase chain reaction (PCR) technique as 
described by Jaradat et al.16 Briefly, PCR was perfor-
med in 96-Well Microplates (Applied Biosystems, 
Thermo Fisher Scientific Inc.) in a 7500 Real-Time PCR 
System (Applied Biosystems, Thermo Fisher Scientific 
Inc.). All assays were performed in quadruplicate. Each 
plate included templates for genomic DNA, negative 
controls and NA07048HM calibrator DNA (Coriell 
Institute for Medical Research, Camden, New Jersey, 
USA) at four copies per genome. Each well contained 
a 20 µL reaction mixture including 4 µL of genomic 
DNA (5 ng/µL), 10 µL of TaqMan® Genotyping Master 
Mix (Thermo Fisher Scientific Inc.) 1 µL of TaqMan® 
Copy Number Assay Mix (Applied Biosystems, 
Thermo Fisher Scientific Inc.), 1 µL of TaqMan® 
Copy Number RNase P Reference Assay mix (Applied 
Biosystems, Thermo Fisher Scientific Inc.) and 4 µL of 
nuclease-free water (Ambion® GmbH, Thermo Fisher 
Scientific Inc.). 
The reaction conditions were as follows: 95 °C 
for 10 minutes for initial denaturation and enzyme 
activation followed by 40 cycles of 95 °C for 15 seconds 
and 60 °C for one minute. Cycle threshold values were 
calculated using the ABI PRISM® 7700 Sequence 
Detection System, Version 1.3 (Applied Biosystems, 
Thermo Fisher Scientific Inc.). Relative quantitation 
was performed using Copy CallerTM Software 
(Applied Biosystems) to estimate the genomic copy 
number in each sample according to the comparative 
cycle threshold method (∆∆Ct). 
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS), 
Version 16.0, (IBM Corp., Chicago, Illinois, USA). 
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Data were presented as the mean estimated copy 
numbers of DEFB4. Each single genomic copy 
number estimate was rounded to the nearest integer 
number. Comparisons between the study groups were 
performed using an unpaired Student’s t-test to assess 
the differences in the means ± standard deviation of 
DEFB4 genomic copy number values. Pearson’s Chi-
squared test was used to analyse categorical data. All P 
values were two-sided and statistical significance was 
set at P ≤0.05. 
This study was approved by the Ethical Committee 
of the Iraqi Board for Medical Specializations 
(approval #3) according to the principles of the 
Declaration of Helsinki. All subjects gave informed 
consent for inclusion in this study. 
Results
A total of 27 BD patients were recruited along with 
50 healthy controls. No significant difference in age 
(P = 0.33) or gender (P = 0.57) was found between the 
groups [Table 1]. The DEFB4 integer genomic copy 
number range was 3–7 copies per diploid genome in 
BD cases compared with 2–6 copies in the control 
group. The mean was 4.44 ± 1.15 copies versus 3.80 ± 
0.92 copies in the BD and control groups, respectively. 
The DEFB4 genomic copy number was significantly 
higher in BD cases than in controls (P = 0.01) [Figure 1]. 
No association was found between the clinical 
presentations of BD and DEFB4 genomic copy 
numbers [Table 2].
Discussion
High DEFB4 genomic copy number values have 
been reported in patients with psoriasis and chronic 
obstructive pulmonary disease.17,18 Previous studies 
have also demonstrated increased DEFB4 messenger 
ribonucleic acid expression of these copy number 
variations on the cellular level and in the mucosal tissues 
of the colon, upper airways and psoriatic skin.9,18–20 In a 
large Chinese sample, significantly higher DEFB4 gene 
numbers were observed among patients with systemic 
lupus erythematosus and anti-neutrophil cytoplasmic 
antibody-associated small vasculitis with a mean 
genomic copy number of 3.98 and 4.05, respectively.21 
Jansen et al. presented evidence that both genomic 
copy number and pro-inflammatory cytokines affect 
the biological levels of hBD-2.20
BD is a good example of a disease rooted in 
immunological disturbance mediated by cytokines 
derived from T-helper lymphocytes, such as TNF-α, 
which acts as a mediator in the initiation and propaga-
tion of BD.22 In this context, TNF-α is a common 
inducer of DEFB4 expression.18 Possible mechanisms 
underlying the uncontrolled inflammatory response 
seen in BD to infection or other environmental triggers 
are either a high basal level of hBD-2 occurring in 
Table 2: Defensin β-4 genomic copy numbers by clinical 
variables among patients with Behçet’s disease in 
Baghdad, Iraq (N = 27)
Clinical 
variable 








17 4.39 ± 9.94 10 4.18 ± 1.19 0.21
Ocular 
lesion
7 4.15 ± 0.20 20 4.36 ± 1.17 0.64
Skin 
lesion
18 4.21 ± 1.03 9 4.46 ± 0.09 0.47





20 4.47 ± 1.11 7 3.79 ± 0.10 1.22
GCN = gene copy number; SD = standard deviation. 
*Determined using the unpaired Student’s t-test.
Figure 1: Frequency of defensin β-4 (DEFB4) genomic 
copy numbers among Iraqi patients with Behçet's disease 
(n = 27) in comparison to healthy controls (n = 50). The 
mean DEFB4 genomic copy number was significantly 
higher in the BD group (P = 0.01).
Table 1: Demographic variables of patients with 
Behçet’s disease in comparison to healthy controls 







Mean age in 
years ± SD









BD = Behçet’s disease; SD = standard deviation. 
*Calculated using the unpaired Student’s t-test. †Calculated using the 
Pearson’s Chi-squared test.
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genetically susceptible individuals with high DEFB4 
genomic copy numbers or high levels of hBD-2 induced 
through the stimulation of TNF-α. It is notable that the 
oral epithelium, the main site of involvement in BD, 
has enriched hBD-2 expression.23 The BD patients in 
the present study showed significantly higher DEFB4 
copy numbers than the healthy controls. Such an 
association between DEFB4 copy numbers and BD has 
not been previously reported. However, no significant 
relationship was observed between genomic copy 
number variations of DEFB4 and the various clinical 
manifestations of BD.
The results obtained from the current study were 
not consistent with previous research from South 
Korea, which found no significant correlation between 
DEFB4 copy numbers and BD.24 These contradictory 
results could be due to several reasons. It is well known 
that the effect of variation in β-defensin genomic copy 
numbers is regarded as complex, rather than simple, 
copy number variation; this is difficult to evaluate in 
small- or moderate-sized case-control studies. As 
a result, very few good candidate genes have been 
accurately studied in genomic association trials.25 The 
results of Aldhous et al. support this observation; in 
spite of a large sample size, they failed to replicate 
both the previously reported high and low genomic 
copy numbers of DEFB4 among patients with Crohn’s 
disease.19,26,27 In addition, discrepancies in assay 
reliability could play a role in explaining differences in 
the obtained results as well as the difference between 
the paralog ratio test used in the Korean study and 
the quantitative PCR assay used in the present study.24 
However, Fernandez-Jimenez et al. demonstrated 
that both techniques can produce comparable DEFB4 
results with the use of optimum DNA normalisation 
and high-quality genomic DNA.28 Nevertheless, it 
is known that DEFB4 copy numbers vary between 
ethnicities;29 this might account for the differences 
observed between the studied Iraqi and Korean 
populations.24 Genetic heterogeneity was observed 
in the β-defensin gene cluster among 67 populations; 
this may have been due to selection.30 Such genetic 
heterogeneity may differ along geographical or racial 
lines in different populations. 
One of the limitations of this study was the small 
sample size. It is important to note that the current 
study simply presents the significantly higher counts 
of mean DEFB4 genomic copies in BD, drawing 
attention to a possible pathological association. 
Further research should focus on the influence of 
these results on hBD-2 levels both in the peripheral 
tissues (especially the orogenital mucosa) and serum 
of BD individuals. Nevertheless, the present study is 
the first to analyse DEFB4 in a cohort of healthy Iraqi 
men and women. The median genomic copy number 
found among this group was similar to the modal 
diplotype genomic copy numbers observed in seven 
different populations.12 A large-scale multicentre study 
is recommended to validate the results of the present 
study and to investigate the functional consequences 
of these copy number variations in terms of hBD-2 
protein expression.
Conclusion 
There was an association between BD and DEFB4 
genomic copy numbers among the studied Iraqi 
subjects, with BD patients having significantly higher 
DEFB4 genomic copy numbers than the control group. 
This suggests that high DEFB4 genomic copy numbers 
may be associated with susceptibility to BD. However, 
no association was found between DEFB4 genomic 
copy numbers and the different clinical manifestations 
of BD. Among the healthy Iraqi control group, the 
median DEFB4 genomic copy number was comparable 
to numbers observed in other populations.
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